Correction to Lancet Oncol 2015; 16: 522-30. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. - Suppr | 超能文献

Correction to Lancet Oncol 2015; 16: 522-30. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial.

作者信息

Eggermont A M M, Chiarion-Sileni V, Grob J-J

出版信息

Lancet Oncol. 2015 Jun;16(6):e262. doi: 10.1016/S1470-2045(15)70271-8. Epub 2015 May 27.

DOI:10.1016/S1470-2045(15)70271-8

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Correction to Lancet Oncol 2015; 16: 522-30. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial.

Lancet Oncol. 2015 Jun;16(6):e262. doi: 10.1016/S1470-2045(15)70271-8. Epub 2015 May 27.

2

Correction to Lancet Oncol 2015; 16: 499-508. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study.《柳叶刀·肿瘤学》2015年第16卷第499 - 508页的勘误。雷莫西尤单抗与安慰剂联合二线FOLFIRI用于在一线使用贝伐单抗、奥沙利铂和氟嘧啶治疗期间或之后进展的转移性结直肠癌患者（RAISE）：一项随机、双盲、多中心、3期研究。

Lancet Oncol. 2015 Jun;16(6):e262. doi: 10.1016/S1470-2045(15)70273-1. Epub 2015 May 27.

3

The current EORTC Melanoma Cooperative Group adjuvant trial programme on malignant melanoma: prognosis versus efficacy, toxicity and costs.

Melanoma Res. 1997 Aug;7 Suppl 2:S127-31.

4

Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial.特泽莫替尼（L-BLP25）联合放化疗对比安慰剂治疗 III 期非小细胞肺癌（START）：一项随机、双盲、III 期临床试验。

Lancet Oncol. 2014 Jan;15(1):59-68. doi: 10.1016/S1470-2045(13)70510-2. Epub 2013 Dec 9.

5

Adjuvant therapy with high dose vitamin D following primary treatment of melanoma at high risk of recurrence: a placebo controlled randomised phase II trial (ANZMTG 02.09 Mel-D).复发高风险黑色素瘤初次治疗后大剂量维生素D辅助治疗：一项安慰剂对照随机II期试验（ANZMTG 02.09 Mel-D）

BMC Cancer. 2014 Oct 24;14:780. doi: 10.1186/1471-2407-14-780.

6

Prospective, randomized, multicenter, double-blind placebo-controlled trial comparing adjuvant interferon alfa and isotretinoin with interferon alfa alone in stage IIA and IIB melanoma: European Cooperative Adjuvant Melanoma Treatment Study Group.前瞻性、随机、多中心、双盲安慰剂对照试验：比较辅助性干扰素α联合异维A酸与单用干扰素α治疗IIA期和IIB期黑色素瘤的疗效——欧洲黑色素瘤辅助治疗协作研究组

J Clin Oncol. 2005 Dec 1;23(34):8655-63. doi: 10.1200/JCO.2004.00.8128. Epub 2005 Oct 31.

7

Melanoma adjuvant therapy.黑色素瘤辅助治疗

Chin Clin Oncol. 2014 Sep;3(3):26. doi: 10.3978/j.issn.2304-3865.2014.03.02.

8

Correction to Lancet Oncol 2015; 16: 324. High-dose radiotherapy with shortterm or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial.

Lancet Oncol. 2015 Jun;16(6):e262. doi: 10.1016/S1470-2045(15)70272-X. Epub 2015 May 27.

9

Immune checkpoint inhibitors in melanoma provide the cornerstones for curative therapies.黑色素瘤中的免疫检查点抑制剂为治愈性疗法奠定了基础。

Semin Oncol. 2015 Jun;42(3):429-35. doi: 10.1053/j.seminoncol.2015.02.010. Epub 2015 Feb 14.

10

Adjuvant ganglioside GM2-KLH/QS-21 vaccination versus observation after resection of primary tumor > 1.5 mm in patients with stage II melanoma: results of the EORTC 18961 randomized phase III trial.辅助神经节苷脂 GM2-KLH/QS-21 疫苗接种与 II 期黑色素瘤患者原发肿瘤切除后 > 1.5 毫米的观察比较：EORTC 18961 随机 III 期试验结果。

J Clin Oncol. 2013 Oct 20;31(30):3831-7. doi: 10.1200/JCO.2012.47.9303. Epub 2013 Sep 9.

引用本文的文献

1

Successful Targeting of CTLA-4 in a Melanoma Clinical Case: A Long-Term "One Stop Therapeutic Shop".成功靶向CTLA-4治疗黑色素瘤临床病例：长期的“一站式治疗方案”

Onco Targets Ther. 2022 Nov 25;15:1409-1415. doi: 10.2147/OTT.S367389. eCollection 2022.

2

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.免疫检查点抑制剂治疗患者免疫相关不良反应的管理：美国临床肿瘤学会临床实践指南。

J Clin Oncol. 2018 Jun 10;36(17):1714-1768. doi: 10.1200/JCO.2017.77.6385. Epub 2018 Feb 14.

3

My personal highlights of ESMO 2016.2016年欧洲肿瘤内科学会（ESMO）大会上我的个人亮点。

Memo. 2017;10(1):46-47. doi: 10.1007/s12254-017-0314-8. Epub 2017 Feb 8.